Study of Blood Flow in Heart Muscle - Full Text View

Purpose

Blood flows to areas of the heart providing oxygen and fuel to the pumping muscle. Occasionally the arteries providing the fuel can become blocked. This occurs in coronary artery disease.

Magnetic resonance imaging (MRI) can be used to evaluate the blood flow to different areas of the heart muscle. In this study magnetic resonance imaging will be compared to other diagnostic tests (radionucleotide perfusion studies) capable of measuring blood flow to heart muscle.

Condition	Intervention	Phase
Coronary Disease Healthy Hypertrophic Cardiomyopathy Myocardial Ischemia	Procedure: Magnetic resonance imaging	Phase II

MedlinePlus related topics:

Cardiomyopathy Coronary Artery Disease MRI Scans

Drug Information available for:

Dipyridamole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Safety/Efficacy Study

Official Title:	Study of Myocardial Perfusion by MRI

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:	249
Study Start Date:	August 1997
Estimated Study Completion Date:	January 2003

Detailed Description:

In this pilot study, magnetic resonance imaging (MRI) of myocardial enhancement during first passage of intravenously injected gadolinium contrast will be used to evaluate regional myocardial perfusion in patients with known or suspected coronary artery disease and hypertrophic cardiomyopathy. The MRI results will be compared with conventional radionuclide perfusion studies (ex. dipyridamole thallium). A clinically defined normal group will also be studied without radionuclide correlation.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

INCLUSION CRITERIA:

Ages 18 to 80.

Either sex.

Capable of giving informed consent.

Group 1: Outpatients with known or suspected coronary artery disease with clinical indication for radionuclide perfusion imaging.

Group 2: Patients with non-obstructive hypertrophic cardiomyopathy with clinical indication for radionuclide perfusion imaging.

Group 3: Normal volunteers.

Positive stress thallium or stress sestamibi (i.e., exercise, adenosine, dobutamine or dypiridamole) at the NIH.

EXCLUSION CRITERIA:

Pregnancy.

Unstable angina.

Uncontrolled hypertension (SBP greater than 185, DBP greater than 105).

Recent myocardial infarction (less than 5 days).

2nd or 3rd degree heart block by ECG.

Asthma, emphysema, renal failure, acute medical illness (fever, pneumonia, etc.) or anemia (hct less than 30).

Cardiac pacemaker or implantable defibrillator, aneurysm clip, neural stimulator, any type of ear implant, metal in your eye, any implanted device (i.e. insulin pump, drug infusion device) or any metallic foreign body, shrapnel, or bullet.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001631

Locations


United States, Maryland
	National Heart, Lung and Blood Institute (NHLBI)
	Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

More Information

Publications:

Wilke N, Simm C, Zhang J, Ellermann J, Ya X, Merkle H, Path G, Ludemann H, Bache RJ, Ugurbil K. Contrast-enhanced first pass myocardial perfusion imaging: correlation between myocardial blood flow in dogs at rest and during hyperemia. Magn Reson Med. 1993 Apr;29(4):485-97.

Matheijssen NA, Louwerenburg HW, van Rugge FP, Arens RP, Kauer B, de Roos A, van der Wall EE. Comparison of ultrafast dipyridamole magnetic resonance imaging with dipyridamole SestaMIBI SPECT for detection of perfusion abnormalities in patients with one-vessel coronary artery disease: assessment by quantitative model fitting. Magn Reson Med. 1996 Feb;35(2):221-8.

Zaman M, Hashmi R, Niaz K, Ahmad A, Kamal S. Safety of pharmacological (intravenous dipyridamole) stress for Thallium-201 perfusion imaging in patients with coronary artery disease unable to exercise. J Pak Med Assoc. 1994 Oct;44(10):237-9.

Study ID Numbers:	970177, 97-H-0177
First Received:	November 3, 1999
Last Updated:	March 3, 2008
ClinicalTrials.gov Identifier:	NCT00001631
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Gadolinium

Ischemia

Coronary Artery Disease

Hypertrophic Cardiomyopathy

Dipyridamole

Study placed in the following topic categories:

Pathological Conditions, Anatomical

Heart Diseases

Myocardial Ischemia

Vascular Diseases

Constriction, Pathologic

Aortic valve stenosis

Healthy

Ischemia

Cardiomyopathies

Heart Valve Diseases

Coronary Disease

Hypertrophy

Cardiomyopathy, Hypertrophic

Dipyridamole

Aortic Valve Stenosis

Coronary Artery Disease

Additional relevant MeSH terms:

Pathologic Processes

Aortic Stenosis, Subvalvular

Cardiovascular Diseases

ClinicalTrials.gov processed this record on November 30, 2008

Sponsored by:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001631